Stock listing

NASDAQ:VRXA Veraxa Biotech AG Stock

Follow Veraxa Biotech AG into a list and get an email when it puts out news.

Share price · NASDAQ:VRXA

$1.04 USD +0.01 (+1.0%)

Close on Nov 20, 2026

Past 6 months -92.0% · daily closes, May 4, 2026 – Nov 20, 2026, adjusted for splits
Day range
$1.03 – $1.06 USDNov 20, 2026
Volume
114,628 sharesNov 20, 2026
Market cap
$147.1M USDAt the close on Nov 20, 2026 · price × 141.4M shares outstanding
Traded on an average day
$364,199 USDMedian day 137,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VRXA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.04+0.01+1.0%$1.03$1.06$1.03114,628
$1.03-0.01-1.0%$1.04$1.07$1.03104,297
$1.04-0.005-0.5%$1.03$1.065$1.03111,524
$1.045-0.065-5.9%$1.08$1.11$1.0455,192
$1.11-0.04-3.5%$1.15$1.18$1.06114,127
$1.15-0.11-8.7%$1.23$1.28$1.14105,720
$1.26+0.19+17.8%$1.10$1.33$1.10270,099
$1.07+0.06+5.9%$1.00$1.15$1.00163,791
$1.01+0.06+6.3%$0.97$1.07$0.938171,879
$0.95-0.002-0.2%$0.96$0.97$0.90222,341
$0.952+0.002+0.2%$1.01$1.05$0.95151,699
$0.95-0.04-4.0%$0.99$1.018$0.95103,122
$0.99-0.04-3.9%$1.02$1.055$0.96253,496
$1.03-0.11-9.6%$1.14$1.15$1.03286,810
$1.14+0.01+0.9%$1.18$1.249$1.075259,928
$1.13+0.15+15.3%$0.97$1.21$0.97363,015
$0.98-0.02-2.0%$1.02$1.02$0.9768,905
$1.00+0.02+2.0%$1.00$1.02$0.9895,381
$0.98-0.02-2.0%$1.00$1.03$0.95161,639
$1.00-0.03-2.9%$1.04$1.06$0.99137,900
$1.03-0.03-2.8%$1.08$1.08$1.03171,300
$1.06+0.05+5.0%$1.05$1.13$1.05198,100
$1.01+0.01+1.0%$1.09$1.09$0.99126,400
$1.00-0.11-9.9%$1.10$1.10$1.00119,000
$1.11+0.01+0.9%$1.15$1.15$1.08125,500
$1.10-0.01-0.9%$1.13$1.15$1.06114,500
$1.11-0.09-7.5%$1.20$1.20$1.0861,500
$1.20+0.06+5.3%$1.20$1.35$1.12741,300
$1.14-0.12-9.5%$1.22$1.30$1.13156,100
$1.26+0.17+15.6%$1.08$1.409$1.071,860,900
$1.09-0.11-9.2%$1.19$1.21$1.09211,900
$1.20+0.12+11.1%$1.16$1.32$1.10749,200
$1.08-0.05-4.4%$1.12$1.147$1.04395,300
$1.130.000.0%$1.13$1.16$1.12153,200
$1.13-0.06-5.0%$1.15$1.15$1.105150,200
$1.19-0.06-4.8%$1.25$1.25$1.1864,900
$1.25-0.06-4.6%$1.31$1.31$1.175119,500
$1.31-0.06-4.4%$1.37$1.37$1.3052,800
$1.37-0.04-2.8%$1.43$1.44$1.3648,500
$1.410.000.0%$1.43$1.45$1.38255,800
$1.41+0.02+1.4%$1.37$1.44$1.3723,300
$1.39-0.02-1.4%$1.44$1.44$1.3843,400
$1.41-0.01-0.7%$1.42$1.436$1.3659,500
$1.42-0.04-2.7%$1.45$1.52$1.4249,100
$1.46-0.01-0.7%$1.50$1.515$1.4516,400
$1.47-0.04-2.6%$1.50$1.53$1.4648,000
$1.51-0.01-0.7%$1.56$1.59$1.49547,600
$1.52-0.11-6.7%$1.61$1.699$1.5052,300
$1.63-0.02-1.2%$1.63$1.72$1.6064,700
$1.650.000.0%$1.68$1.72$1.6288,900
$1.65+0.06+3.8%$1.58$1.682$1.57400,100
$1.59-0.01-0.6%$1.62$1.65$1.56188,500
$1.60-0.16-9.1%$1.81$1.90$1.56468,700
$1.76+0.23+15.0%$1.57$1.97$1.5313,582,300
$1.53+0.15+10.9%$1.38$1.68$1.371560,000
$1.38-0.02-1.4%$1.42$1.435$1.36176,200
$1.40+0.05+3.7%$1.38$1.543$1.27384,800
$1.350.000.0%$1.39$1.39$1.32296,300
$1.35-0.09-6.2%$1.43$1.45$1.32313,600
$1.44-0.20-12.2%$1.65$1.685$1.365495,000
$1.64-0.09-5.2%$1.85$1.85$1.57425,400
$1.73-0.05-2.8%$1.78$1.825$1.72145,700
$1.78-0.17-8.7%$1.98$2.00$1.75301,900
$1.95+0.06+3.2%$1.86$2.00$1.8580,200
$1.89+0.03+1.6%$1.88$1.95$1.8537,100
Ticker
NASDAQ:VRXA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Veraxa Biotech AG news

Veraxa Biotech AG on 6ix

Sector
Health care
Industry
Biotechnology
News releases
42 in the last 12 months · 42 in all · newest Oct 13, 2026 · oldest 2026
Decks
1 deck · latest Apr 23, 2025

Valuation

EV/sales 5,202× against a median of 2.7×: the highest of 7 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · price Nov 20, 2026

Enterprise value
$145.1M USD
P/E
Loss
EV/sales
5,202×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
66.0%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
Negative equity
Beta vs S&P 500
1.11

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Veraxa Biotech AG · NASDAQ:VRXAUS$147.1MUS$145.1Mn/a5,202×n/an/an/an/a1.11
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H · HKEX:1541US$152.0MUS$64.59Mn/a2.9×n/a1.6×−141.7%0.6×n/a
Saniona AB · OMXSTO:SANIONUS$151.6MUS$104.0M8.4×2.5×5.2×2.8×43.2%0.0×n/a
Palisade Bio, Inc. · NASDAQ:PALIUS$150.6MUS$36.96Mn/a73.9×n/a1.3×n/a0.0×1.41
Eledon Pharmaceuticals, Inc. · NASDAQ:ELDNUS$150.3MUS$80.67Mn/an/an/a4.9×n/a0.0×1.95
ProQR Therapeutics N.V. · NASDAQ:PRQRUS$146.8MUS$49.73Mn/a2.2×n/a2.0×−210.7%0.2×1.73
ALX Oncology Holdings Inc. · NASDAQ:ALXOUS$146.6MUS$9.57Mn/an/an/a1.2×n/a0.1×0.68
Bicycle Therapeutics PLC · NASDAQ:BCYCUS$146.1M−US$323.8Mn/a−3.9×n/a0.3×−169.8%0.0×1.59
BridgeBio Oncology Therapeutics, Inc. · NASDAQ:BBOTUS$145.3M−US$46.23Mn/an/an/a0.5×n/a0.0×1.49
TYK Medicines, Inc. Class H · HKEX:2410US$144.9MUS$137.1Mn/an/an/a3.7×n/a0.6×n/a
Sutro Biopharma, Inc. · NASDAQ:STROUS$142.8MUS$259.6Mn/a5.8×n/an/a−344.2%n/a1.14
Median of the othersUS$146.7MUS$57.16M8.4×2.7×5.2×1.6×−169.8%0.0×1.49

Team and board

Officers

OfficerRole
Carl von HalemInterim Chief Financial Officer and Successor to Torsten Bürgermeister
Raju WillenerMBA, CFO
Christoph ErkelPh.D., CSO

Board

DirectorRole
Oliver R. BaumannChair of the Board
Christoph AntzDirector
Christoph ZieglerIndependent Director
Marc GrüningerChair of the Audit Committee
Warren HosseinionIndependent Director

Decks

DeckKindSlidesDate
SPAC Merger (April 2025)SPAC merger28 slidesApr 23, 2025

Open Decks

Financials

Annual, in CHF

Income statement

LineFY2025FY2024FY2023
Revenue23.4K00
Cost of revenue7.96K0
Gross profit15.5K0
Research and development10.3M6.31M4.26M
Selling, general and administrative53.9M20.7M10.5M
Operating income-66.2M-28.9M-16.7M
Depreciation and amortization1.97M1.88M1.85M
EBITDA-64.2M-27.0M-14.8M
Interest expense3.55K2911.09K
Income before tax-67.0M-28.8M-17.7M
Net income-66.6M-28.1M-16.5M
Earnings per share, basic-0.47-0.20-0.12

Balance sheet

LineFY2025FY2024FY2023
Cash and equivalents1.61M5.36M11.4M
Current assets2.88M5.61M11.9M
Goodwill22.8M22.8M22.8M
Total assets80.8M84.8M91.9M
Accounts payable1.39M488.5K611.6K
Current liabilities6.61M2.55M1.61M
Total liabilities96.6M53.7M36.8M
Shareholders' equity-15.8M31.1M55.1M
Shares outstanding141.4M141.4M141.4M

Cash flow

LineFY2025FY2024FY2023
Cash from operations-9.90M-7.72M-7.27M
Capital spending-437.2K-120.9K-232.3K
Free cash flow-10.3M-7.84M-7.50M
Cash from financing6.59M1.85M12.5M
Change in cash-3.75M-5.99M4.25M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 19, 2026Current reportSEC
4 · Change in ownershipOct 29, 2026Insider tradeSEC
4 · Change in ownershipOct 21, 2026Insider tradeSEC
6-K · Report of a foreign issuerOct 15, 2026Current reportSEC
3 · Initial statement of ownershipSep 14, 2026Insider tradeSEC
424B3 · ProspectusSep 4, 2026Offer documentSEC
424B3 · ProspectusSep 4, 2026Offer documentSEC
6-K · Report of a foreign issuerSep 4, 2026Current reportSEC
4 · Change in ownershipAug 31, 2026Insider tradeSEC
4 · Change in ownershipAug 31, 2026Insider tradeSEC
All 57 filings
FilingDateTypeFiled with
6-K · Report of a foreign issuerAug 24, 2026Current reportSEC
3 · Initial statement of ownershipAug 20, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
424B5 · ProspectusAug 10, 2026Offer documentSEC
424B5 · ProspectusAug 10, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 10, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveAug 7, 2026Other filingsSEC
F-1/A · Registration statement, amendedAug 5, 2026Offer documentSEC
F-1/A · Registration statement, amendedAug 5, 2026Offer documentSEC
F-1 · Registration statementJul 31, 2026Offer documentSEC
F-1 · Registration statementJul 31, 2026Offer documentSEC
6-K · Report of a foreign issuerJul 31, 2026Current reportSEC
6-K · Report of a foreign issuerJul 27, 2026Current reportSEC
6-K · Report of a foreign issuerJul 27, 2026Current reportSEC
6-K · Report of a foreign issuerJun 18, 2026Current reportSEC
20-F · Annual reportJun 16, 2026Annual reportSEC
SCHEDULE 13D · Big-stake noticeJun 16, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeJun 16, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeJun 15, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeJun 15, 2026Big-stake noticeSEC
6-K · Report of a foreign issuerJun 10, 2026Current reportSEC
CERT · Exchange's certificate of listingJun 10, 2026Other filingsSEC
8-A12B/A · Registration of shares for listing on an exchange, amendedJun 10, 2026Other filingsSEC
3 · Initial statement of ownershipJun 10, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 10, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 9, 2026Insider tradeSEC
8-A12B · Registration of shares for listing on an exchangeJun 9, 2026Other filingsSEC
424B3 · ProspectusFeb 19, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 18, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 13, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 12, 2026Other filingsSEC
F-4/AFeb 12, 2026Offer documentSEC
UPLOAD · Letter from the SECFeb 11, 2026Other filingsSEC
F-4/AFeb 3, 2026Offer documentSEC
CORRESP · Letter to the SECNov 28, 2025Other filingsSEC
F-4/ANov 28, 2025Offer documentSEC
UPLOAD · Letter from the SECNov 20, 2025Other filingsSEC
425Sep 30, 2025Other filingsSEC
F-4/ASep 29, 2025Offer documentSEC
CORRESP · Letter to the SECSep 29, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 27, 2025Other filingsSEC
F-4/AJul 31, 2025Offer documentSEC
F-4Jul 30, 2025Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Veraxa Biotech AG’s releases

Common shares
141,407,813
Fully diluted
141,407,813

Fully diluted

LineShares
Common shares141,407,813

Share count over time

CountShares
Nov 22, 2026141,407,813

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Gruninger Marc
Director
Buy9,133USD 1.00US$9,133Oct 28, 2026
Gruninger Marc
Director
Buy867USD 0.98US$850Oct 27, 2026
Ziegler Christoph Samuel
Director
Buy30,000USD 1.09US$32,700Oct 20, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Warren Hosseinion
Other companies: Cardio Diagnostics Holdings Inc. (Non-Executive Chairman of the Board · Since at least Nov 5, 2026); General Purpose Acquisition Corp. (Director · Since at least Dec 2, 2025); Nutex Health Inc. (President and Director · Since at least Mar 1, 2025)
Independent Director · Since at least Jun 9, 2026
Carl von HalemInterim Chief Financial Officer and Successor to Torsten Bürgermeister · Since at least Jul 10, 2026
Christoph AntzDirector · Since at least Jun 9, 2026
Christoph ErkelPh.D., CSO · Since Jul 23, 2026
Christoph ZieglerIndependent Director · Since at least Jun 9, 2026
Heinz SchwerChief Business Officer · Since at least Jun 9, 2026
Marc GrüningerChair of the Audit Committee · Since at least Jun 9, 2026
Oliver R. BaumannChair of the Board · Since at least Jun 9, 2026
Raju WillenerMBA, CFO · Since at least Sep 1, 2026
Torsten Georg Friedrich BuergermeisterChief Financial Officer · Since at least Jun 9, 2026

Open People

Log in to ask 6ix AI your own questions about Veraxa Biotech AG.